Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China ...Middle East

SHANGHAI and SUZHOU, China, March 21, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This...

Hence then, the article about harbour biomed announces dosing of first patient in phase i clinical study of its next generation anti ctla 4 antibody in china was published today ( Monday 22/03/2021 - 04:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China )

Also on site :

• 'We've lost our way': Clifton's operator gives up on downtown Los Angeles
• Iran has learned that the Strait of Hormuz is its strongest deterrent
• Disney World Just Dropped the Opening Date for the Muppets Rock 'n' Roller Coaster and Your Summer Plans Are Officially Set